# Pizarra — PT-pseudo_075dd468b384 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_075dd468b384
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.14 ng/mL²
  - PSA velocity: 2.7 ng/mL/yr
  - Prior PSA: 10.2 ng/mL
  - Prostate volume: 96.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6351894 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia
  - Current medication: amlodipine, atorvastatin, simvastatin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.2 ng/mL. PI-RADS 4. PSAD 0.14. Prostate volume 96 mL. DRE nodus. csPCa 0.64.

Vitals: weight 60 kg, height 178 cm, BMI 18.9, BP 146/82 mmHg, HR 70 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2010).

Chief complaint: Specialist reassessment sought due to a steadily rising PSA curve alongside historical biopsy results.

History: A 66-year-old office administrator arrives for specialist review after an initial PSA elevation in 2022. Married and settled in an independent unit of a retirement community, he walks 45 minutes daily and avoids alcohol entirely. His medical background encompasses hypertension and hypercholesterolaemia, treated with amlodipine, atorvastatin, and simvastatin. A substantial smoking history of 33 pack-years was concluded in 2010. Lower urinary tract complaints remain mild, scoring 5 out of 35 on the IPSS. Documented hypersensitivity to NSAIDs exists, necessitating large-print correspondence, and his brother serves as his designated next of kin. Unrelated to the current urological focus, he had uncomplicated cataract extraction in 2018, recently visited a sleep clinic for suspected obstructive sleep apnoea, and maintains routine podiatry appointments for foot care.

Physical examination: DRE — texture: firm; asymmetry: present; location: left posterior peripheral zone (Nodus). The remainder of the abdominal and cardiovascular assessment proves unremarkable, recording a blood pressure of 146/82 mmHg and a heart rate of 70 bpm. General inspection reveals a slender physique with a BMI of 18.9, alongside adequate nutritional status and an absence of acute distress.

Patient info: office administrator; Married; Lives in retirement community (independent unit).
Next of kin: Sibling (brother).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 45 min/day; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Sleep clinic — suspected obstructive sleep apnoea; Podiatry — routine foot care.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.20   (95% CI 0.07-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=13.2, age=66.0, psad=0.14, dre_ord=1.0, vol=96.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the PSA velocity (2.7 ng/mL/yr) and the prior PSA (10.2 ng/mL) against the current PSA (13.2 ng/mL), which suggests a rapid rise. It also could not incorporate the specific findings from the mpMRI report (PI-RADS 4) in conjunction with the PSA velocity, which is a critical combination. Finally, it could not assess the context provided by the previous notes regarding the prior positive biopsy status, which heavily influences the interpretation of the current findings.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.41 +/- 0.20), indicating high uncertainty. The internal contradiction lies in the high csPCa predicted probability (0.6351894) and the PI-RADS 4 score, which typically suggest a need for further investigation, yet the prior leans towards no biopsy. Furthermore, the prior does not account for the fact that the patient has a 'Positive' prior biopsy status, which fundamentally changes the question from "Does he have cancer?" to "Is the cancer progressing/recurrent?"

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intra-prostatic extension or high-risk features, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning trajectory, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> If these notes detail the clinical reasoning for the prior positive biopsy, it would refine the interpretation of the current situation.
  <document> laboratory results (full panel) -> If the lab panel shows any markers that might suggest aggressive disease or other comorbidities influencing the decision, it would refine the decision.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_075dd468b384", "radiology_report": "Amsterdam UMC \u2013 Radiology Division\nDate: 10 Jan 2025 | Modality: Multiparametric MRI Prostate\n\nClinical context: Risk reassessment following a PSA reading of 13.2 ng/mL and a previously positive biopsy. Initial screening flagged a potential PI-RADS 4 focus.\n\nImaging Details: The gland demonstrates marked hypertrophy, totaling 96.0 mL in overall volume. Within the left mid-gland peripheral zone, a 12 x 8 mm focus exhibits restricted diffusion on DWI/ADC alongside early enhancement on DCE sequences. T2-weighted sequences reveal intermediate signal intensity; capsular integrity remains intact with no seminal vesicle involvement. Benign nodular hyperplasia diffusely expands the transition zone.\n\nImpression:\nPI-RADS 4 lesion in the left mid-gland peripheral zone.\nProstate volume 96.0 mL yielding a PSA density of 0.14 ng/mL/mL.\ncsPCa predicted probability 0.6351894."}

  **psa_trend**
  {"case_id": "PT-pseudo_075dd468b384", "psa_trend": [{"date": "Aug 2022", "val": 1.6}, {"date": "Jun 2023", "val": 3.2}, {"date": "Mar 2024", "val": 6.5}, {"date": "Jan 2025", "val": 13.2}]}

  **previous_notes**
  {"case_id": "PT-pseudo_075dd468b384", "previous_notes": [{"date": "17 May 2024", "author": "Dr. L. Smits (GP)", "text": "17 May 2024 \u2013 Dr. L. Smits (GP): A routine follow-up encounter took place. Laboratory data from March 2024 indicate a PSA level of 10.2 ng/mL, reflecting a steady climb from the first elevation noted in 2022. The patient continues amlodipine and statin therapy to manage hypertension and hypercholesterolaemia, demonstrating consistent compliance. Relevant laboratory and imaging documentation was transmitted to the urology department."}, {"date": "14 Sep 2024", "author": "Dr. L. Smits (GP)", "text": "14 Sep 2024 \u2013 Dr. L. Smits (GP): A consultation addressed the continuing urological evaluation. Blood pressure remains stable under the current therapeutic regimen, and lipid parameters are steady following an autumn cardiology assessment. The individual reports only baseline mild urinary frequency without additional complaints. Overall health status shows no deviation."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_075dd468b384", "laboratory_results": [{"name": "PSA", "val": "13.2 ng/mL", "date": "18 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.57 ng/mL", "date": "18 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "18 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "18 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.6 x10^9/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "302 x10^9/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "87 umol/L", "date": "18 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "17.3 nmol/L", "date": "18 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "83 U/L", "date": "18 Dec 2024", "flag": ""}, {"name": "LDH", "val": "147 U/L", "date": "18 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.6 %", "date": "18 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history: Not called because the retrieval of other documents provided sufficient context regarding the clinical picture and prior management.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 4 lesion in the left mid-gland peripheral zone
  - PSA velocity of 2.7 ng/mL/yr (from trend data)
  - csPCa predicted probability of 0.6351894

  AGAINST sampling this patient now:
  - Prior biopsy was Positive
  - Free PSA is 12% (which can sometimes be reassuring, though context is needed)

WHERE THIS LEANS
  The retrieved evidence strongly suggests a need for further investigation due to the PI-RADS 4 finding and the rising PSA velocity, which aligns with the concern raised by the LLM-1-GAP-ANALYST. This leans towards recommending a biopsy to clarify the nature of the progression following the prior positive result.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the patient presents with a PI-RADS 4 lesion and a rising PSA velocity of 2.7 ng/mL/yr, which strongly suggests progression following a prior positive biopsy. The combination of the PI-RADS 4 finding and the rising PSA trajectory, despite the prior positive result, mandates further tissue sampling to assess the current disease status. The statistical prior suggested deferral, but the retrieved evidence of high-risk imaging and PSA velocity overrides this initial suggestion.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
